Monday, November 25, 2024
Home Authors Posts by Editor / Curator

Editor / Curator

928 POSTS 0 COMMENTS
Superbug News - CoronaVirus Watch List

Drug Resistance Could Kill 10M People per year by 2050, Experts...

Editor / Curator -
Superbug News - CoronaVirus Watch List

CDC’s Worst-Case Coronavirus Model: 214 Million Infected, 1.7 Million Dead (Intelligencer)

Editor / Curator -
CoronaVirus

‘Amazing potential.’ UM doctor to start stem cell trial for coronavirus...

Editor / Curator -
American BriVision
Biotech News

American BriVision (ABVC) Improves Working Capital and Reduce Debt.

Editor / Curator -
All News

FDA Authorizes Athersys (ATHX) to Initiate a Pivotal Clinical Trial!

Editor / Curator -
Biotech News

Qiming Venture Partners Raises $1.1 Billion Fund VII

Editor / Curator -
Biotech Stock Review, Exsosomes
Biotech News

Exosomes, Extracellular Vesicles, and the CoronaVirus.

Editor / Curator -
Corbus Pharma, Biotech Stock Review
All News

Adding Corbis Pharma (CRBP) $5.55 to Watch List.

Editor / Curator -
Athersys, Biotech Stock Review
Superbug News - CoronaVirus Watch List

Boo Ya. Brokerage Sets $12 Price Target for Athersys (ATHX) $2.96.

Editor / Curator -
Superbug News - CoronaVirus Watch List

Adding Organicell (BPSR) $0.02 to the Watch List.

Editor / Curator -
1...686970...93Page 69 of 93

Latest article

Nine Page Summary Report on GeoVax (GOVX)

2024 Watch List Editor / Curator -
This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

GeoVax (GOVX) Provides First Half 2024 Business Update.

2024 Watch List Editor / Curator -
Award of BARDA Project NextGen contract represents a significant milestone event; Total value...

Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.

All News Editor / Curator -
Can You Imagine Selling Solgenix at $2.00 yesterday. And to be honest, news wasn't all that big - such...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: [email protected]
© Managed by Revelers.IO Media Group Inc.